噬菌体作为抗生素的佐剂治疗由耐多药铜绿假单胞菌引起的人工关节感染。
Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa.
机构信息
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Center for Musculoskeletal Surgery, Berlin, Germany
Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.
出版信息
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.00924-19.
Abstract
We documented the adjunctive bacteriophage therapy to treat a chronic relapsing periprosthetic joint infection of the knee and chronic osteomyelitis of the femur caused by multidrug-resistant The combined antibiotic-phage treatment eradicated the infection, and no side effects to phages were observed.
摘要
我们记录了辅助噬菌体治疗治疗慢性复发性膝关节假体关节感染和由多药耐药引起的慢性股骨骨髓炎。联合抗生素噬菌体治疗根除了感染，并且没有观察到噬菌体的副作用。
相似文献
1
Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.00924-19.
2
Successful Bacteriophage-Antibiotic Combination Therapy against Multidrug-Resistant Left Ventricular Assist Device Driveline Infection.
Viruses. 2023 May 20;15(5):1210. doi: 10.3390/v15051210.
3
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Infection. 2018 Apr;46(2):263-265. doi: 10.1007/s15010-017-1086-0. Epub 2017 Oct 31.
4
Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
J Antimicrob Chemother. 2015 Dec;70(12):3357-65. doi: 10.1093/jac/dkv281. Epub 2015 Sep 28.
5
Combinations of Bacteriophage Are Efficacious against Multidrug-Resistant and Enhance Sensitivity to Carbapenem Antibiotics.
Viruses. 2024 Jun 21;16(7):1000. doi: 10.3390/v16071000.
6
Engineered Bacteriophages Containing Anti-CRISPR Suppress Infection of Antibiotic-Resistant P. aeruginosa.
Microbiol Spectr. 2022 Oct 26;10(5):e0160222. doi: 10.1128/spectrum.01602-22. Epub 2022 Aug 16.
7
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
AAPS J. 2019 Apr 4;21(3):49. doi: 10.1208/s12248-019-0315-0.
8
Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01714-17. Print 2018 Feb.
9
Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.
Infection. 2019 Aug;47(4):665-668. doi: 10.1007/s15010-019-01319-0. Epub 2019 May 17.
10
Bacteriophage Therapy Increases Complement-Mediated Lysis of Bacteria and Enhances Bacterial Clearance After Acute Lung Infection With Multidrug-Resistant Pseudomonas aeruginosa.
J Infect Dis. 2019 Apr 16;219(9):1439-1447. doi: 10.1093/infdis/jiy678.
引用本文的文献
1
Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.
Cell Surf. 2025 Jul 3;14:100149. doi: 10.1016/j.tcsw.2025.100149. eCollection 2025 Dec.
2
Current Applications and the Future of Phage Therapy for Periprosthetic Joint Infections.
Antibiotics (Basel). 2025 Jun 6;14(6):581. doi: 10.3390/antibiotics14060581.
3
Present and future of microbiome-targeting therapeutics.
J Clin Invest. 2025 Jun 2;135(11). doi: 10.1172/JCI184323.
4
The virulent bacteriophage Henu8 as an antimicrobial synergist against .
Microbiol Spectr. 2025 Jul;13(7):e0163324. doi: 10.1128/spectrum.01633-24. Epub 2025 May 16.
5
Emerging antimicrobial therapies for Gram-negative infections in human clinical use.
NPJ Antimicrob Resist. 2025 Feb 27;3(1):16. doi: 10.1038/s44259-025-00087-2.
6
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.
Int J Mol Sci. 2025 Feb 19;26(4):1755. doi: 10.3390/ijms26041755.
7
Phage Therapy Against Antibiotic-Resistant and Multidrug-Resistant Infections Involving Nonhealing Wounds and Prosthetic Joint Infections Associated With Biofilms: A Mini-Review.
Can J Infect Dis Med Microbiol. 2024 Nov 7;2024:6252415. doi: 10.1155/2024/6252415. eCollection 2024.
8
Phages ZC01 and ZC03 require type-IV pilus for infection and have a potential for therapeutic applications.
Microbiol Spectr. 2024 Oct 29;12(12):e0152724. doi: 10.1128/spectrum.01527-24.
9
bacteriophage against carbapenem-resistant of capsular type 64.
Front Microbiol. 2024 Sep 23;15:1462459. doi: 10.3389/fmicb.2024.1462459. eCollection 2024.
10
Current status of clinical trials for phage therapy.
J Med Microbiol. 2024 Sep;73(9). doi: 10.1099/jmm.0.001895.
本文引用的文献
1
Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00229-19. Print 2019 Aug.
2
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.
Cell Host Microbe. 2019 Feb 13;25(2):219-232. doi: 10.1016/j.chom.2019.01.014.
3
Perspectives of Phage Therapy in Non-bacterial Infections.
Front Microbiol. 2019 Jan 9;9:3306. doi: 10.3389/fmicb.2018.03306. eCollection 2018.
4
Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro.
PLoS One. 2019 Jan 16;14(1):e0209390. doi: 10.1371/journal.pone.0209390. eCollection 2019.
5
Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections.
Viruses. 2018 Dec 28;11(1):18. doi: 10.3390/v11010018.
6
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
Front Cell Infect Microbiol. 2018 Oct 23;8:376. doi: 10.3389/fcimb.2018.00376. eCollection 2018.
7
Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus.
Int J Antimicrob Agents. 2018 Dec;52(6):842-853. doi: 10.1016/j.ijantimicag.2018.09.006. Epub 2018 Sep 17.
8
Real-time assessment of bacteriophage T3-derived antimicrobial activity against planktonic and biofilm-embedded Escherichia coli by isothermal microcalorimetry.
Res Microbiol. 2018 Nov;169(9):515-521. doi: 10.1016/j.resmic.2018.05.010. Epub 2018 Jun 7.
9
Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Biofilms.
Front Microbiol. 2018 Feb 5;9:127. doi: 10.3389/fmicb.2018.00127. eCollection 2018.
10
Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials.
Methods Mol Biol. 2018;1693:159-170. doi: 10.1007/978-1-4939-7395-8_14.
Zotero 插件